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Abstract
The early identification of pre-lingual deafness is necessary to minimize the consequences of hearing impairment
on the future communication skills of a baby. According to the most recent international guidelines the deafness
diagnosis must occur before the age of three months and the prosthetic-rehabilitative treatment with a traditional
hearing aid should start within the first six months. When a Cochlear implant becomes necessary, the treatment
should start between the age of 12 months and 18 months. The only way to diagnose the problem early is the
implementation of universal neonatal audiological screening programs. Transient evoked otoacoustic emissions
(TEOAE) is the most adequate test because it’s accurate, economic and of simple execution. Automatic auditory
brainstem response (AABR) is necessary to identify patients with auditory neuropathy but it is also important to
reduce the number of false-positives.The 20-30% of infant hearing impairment is represented by progressive or
late-onset hearing loss (HL) so it’s also necessary to establish an audiological follow up program, especially in
infants at risk.
From November 2005 all neonates born in the University hospital of Pisa undergo newborn hearing screening.
From 2008 the screening program follows the guidelines for the execution of the audiological screening in
Tuscany which have been formulated by our group according to the 2007 JCIH Position Statement and adaptated
to our regional reality by a multidisciplinary effort. From November 2005 to April 2009 8113 neonates born in the
Neonatal Unit of Santa Chiara Hospital (Pisa) have undergone newborn hearing screening. 7621 neonates (93.9%)
without risk factors executed only the TEOAE test. 492 (6.1%) neonates had audiological risk factors and thus
underwent TEOAE and AABR. 84 patients (1,04%) failed both TEOAE and AABR tests. 78 of them underwent further
investigations. 44 patients resulted falsepositives (the 0,54% of the screened newborns). 34 neonates (4,2 ‰) had a
final diagnosis of hearing impairment. 8 patients (0.99 ‰) had unilateral hearing loss (HL). 26 patients (3,2 ‰) had
bilateral hearing impairment.
In our screening program the percentage of false-positives was quite low (0.54%) while the incidence of bilateral
HL (3.2 ‰) is a little higher than that found in literature reports. In most of our patients premature birth or
neonatal suffering represent the main cause of HL.
Introduction
The identification and the early diagnosis of pre-lingual
deafness is necessary to prevent or minimize the serious
consequences of hearing impairment on language devel-
opment and on the future communication skills of a
baby [1-7].
According to the most recent international guidelines
the deafness diagnosis must occur before the age of
three months and the prosthetic-rehabilitative treatment
with a traditional hearing aid should start within the
first six months. When a Cochlear implant becomes
necessary, the treatment should start between the age of
12 months and 18 months [8-14]. Pre-lingual deafness is
a silent pathology which often becomes evident only
after causing serious consequences on the acquisition
and development of language abilities. The only way to
early diagnose the problem is the implementation of
universal neonatal audiological screening programs [5].
The aim of such programs is to identify hearing
impairments present at birth, overall medium and severe
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[15-21,6,7].
The most important international guidelines suggest
the execution of a universal screening program and
hence screening tests should be done on all neonates
and not only on those presenting increased risk factors
[ 5 - 7 , 2 2 ] ,a so n l ya b o u th a l fo ft h eb a b i e ss u f f e r i n gf r o m
permanent hearing conditions present increased risk
factors [22-28].
Actually in Italy neonates without risk factors are
tested at around 8 months of age with the use of the
Boel test. Boel test is difficult to execute (it requires spe-
cific expertise) and it successfully identifies only less
than half of babies with a hearing impairment. That
explains why, in the absence of a screening program,
the average delay in the diagnosis ranges between
18 months and 24 months. Such delay might cause a
decreased effectiveness of the rehabilitation therapy and
irreparable consequences for the patient [7,12-14,29,30].
The aim of the universal screening is hence to identify
as early as possible the highest number of infants with
permanent bilateral hearing impairments [6,7,15,22,31].
Recent screening methodologies (TEOAE and AABR)
are completely risk-free and extremely accurate [6,7,32].
When the latest technology is used in conjunction
with specific operator training, the accuracy of screening
programs can be close to 100% with a specificity of
about 97-98%. That means that virtually all neonates
with a hearing impairment greater than 40dB will be
identified, while about 2-3% of the babies diagnosed
will be false positives. The false positives are later re-
examined and a large part of them subsequently
presents normal hearing function [33-35].
In the last 10 years a new clinical/audiological entity
has been defined (but not completely understood): the
auditory neuropathy. Auditory neuropathy is charac-
terised by normal otoacoustic emissions and altered
auditory brainstem response, due to damage either to
the inner hair cells, damage to the acoustic nerve fibres
or to the synaptic junction between them and inner hair
cells [32,36-38].
Neonates affected by auditory neuropathy can be diag-
nosed only by executing the ABR test (automatic or
clinical) in conjunction with otoacoustic emissions.
A TEOAE test in this cases would lead to a falsely nega-
tive outcome. For these reasons it is necessary to test
neonates with auditory neuropathy risk factors with
both TEOAE and AABR tests [7,36].
In the last few years there has been an increased focus
on late onset hearing loss. Progressive or late onset deaf-
ness can have different causes (genetic predisposition,
infections etc.) and represents a relatively large percen-
tage (20-30%) of hearing loss in children, even if reliable
statistics are not available internationally [39]. Babies
affected with progressive or late onset deafness may not
be identified with neonatal hearing screening and might
be identified only by a long term paediatric surveillance
program.
The Joint Committee on Infant Hearing (JCIH) in the
2007 Position Statement has identified the issue of late
onset hearing loss and has defined the risks factors that
requires an audiological follow-up during the first years
of life [7].
With the Regional Decree n.365 of May 21st 2007, the
local regional government of Tuscany (Regione Toscana)
has made compulsory the execution of the neonatal
audiological screening program in all the birth centers
of the region.
We have subsequently written the “Guidelines for the
execution of the neonatal audiological screening” together
with the Department of Audiology of the Careggi Hospital
(headed by Prof P Pagnini) and with the Audiology
Department of the University of Siena (headed by Prof W
Livi). The guidelines were approved by the Consiglio Sani-
tario Regionale Toscano (Tuscan Regional Health Council)
in June 2008 and are today a reference for all the hospitals
and operators (neonatologists, paediatricians, otorhinolar-
yngologists, audiologists, audiometrists, paediatric nurses,
child neuropsychiatrists, geneticists) executing screening
programs in Tuscany. Our guidelines are based on the
ones created by the JCIH in 2007, but have been modified
by a multidisciplinary effort and adapted to our regional
reality. Follows a brief example showing the methods of
screening execution in Tuscany.
Screening execution details in Tuscany
The screenings can be executed in three different types of
hospitals which are distinguished by their level. A centre
is assigned a level depending on the type of instruments
and diagnostic equipment available.
Level I facilities: these facilities can only execute
TEOAE tests with latest available diagnostic instruments.
The test is executed by audiometrists, audiologists, pae-
diatricians, paediatric nurses or otorhinolaryngologists
after a specific training.
Level II facilities: these facilities have the latest avail-
able instruments necessary to execute TEOAE and
A A B Rt e s t s .A l s oi nt h i sc a s e the test is executed by
trained audiometrists, audiologists, paediatricians, pae-
diatric nurses or otorhinolaryngologists.
Level III facilities (reference hospitals): these hospi-
tals have the latest equipment for the execution of
TEOAE, AABR and they are also capable of executing
clinical ABR, clinical TEOAE and DPOAE (distortion
produced otoacoustic emissions), impedence audiometry
and infant audiometric testing.
All these diagnostic tests are executed by personnel
with a specific expertise in this field. Level III facilities
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causes of the hearing impairment and the initiation of a
prosthetic/rehabilitative treatment. Each facility should
at first classify neonates depending on whether they pre-
sent auditory neuropathy risk factors or no because well
babies and neonates at risk should perform different
kind of screening test battery.
In all cases the screening must be executed before dis-
charging the neonate from hospital and positive tests
might be repeated within two weeks after birth. Each
local health authority should nominate a person in
charge of the screening procedures in each facility. This
person might be a paediatrician, neonatologist, audiolo-
gist or an otorhinolaryngologist and he/she should
involve the audiometrists and the paediatric nurses in
the process. In general is advised that the screening
should be performed only by dedicated personnel with a
specific training and not by generic health operators.
Especially in facilities of Level II and III, the screening
should be performed by audiometrists and there should
be a close collaboration between the Neonatal Units and
the Audiology Units.
The Clinical Physiology Institute of the CNR (National
Council for Research) is developing a database that will
be used by all regional facilities to file and retrieve neo-
natal audiological screening data. Such data will then be
made available online. This will allow a monitoring on
the effectiveness of the screening program (a screening
program is considered adequate when it’se x e c u t e do n
more than 95% of neonates and it identifies at least 99%
of the hearing loss cases with only less than 2-3% of
false positives).
All these entities will need to establish the details of the
screening execution for the babies born in private clinics,
babies born at home, in other Italian regions or other
countries. All these babies will need to be screened
within a month from birth or within a month from the
moment they are assigned to a family paediatrician.
1. Screening in well babies (fig 1)
Dedicated personnel (audiometrists, neonatologist,
audiologist, otorhinolaryngologist or paediatric nurses)
should execute the TEOAE test 24 hours after birth.
Tests should be performed in silent rooms while the
neonates are asleep or when they are most quiet (for
example after feeding). If the test outcome is negative
(pass) for both ears the audiological screening is consid-
ered successfully completed. If instead the test outcome
is positive (refer) for one or both ears then the TEOAE
test should be repeated before the infant is discharged
from hospital. If this second test still produces a positive
result the infant should undergo a AABR test. Level I
facilities should send these neonates to level II or level
III facilities where AABR can be performed. AABR
should be executed within 30 days from birth. If the
complete test (TEOAE+AABR) outcome is positive,
infants should undergo further tests in a level III facility,
within 90 days from birth, such as clinical ABR, clinical
TEOAE etc. Level III facilities should then start the
investigation on the causes of the hearing impairment
and should initiate a prosthetic/rehabilitative treatment
within 6 months from birth.
Congenital infections from Cytomegalovirus (CMV)
should be immediately investigated in all infants that
result positive at the first level audiological screening
(TEOAE), researching CMV DNA in urine.
2. Screening in neonates with auditory neuropathy risk
factors (fig 2)
Auditory neuropathy risk factors are:
- neonatal intensive care of more than 5 days or any
of the following regardless of length of stay (ECMO,
assisted ventilation, exposure to ototoxic medications
TEOAE in the 2nd day of life
Further audiological investigation
within 3 months of life
Prosthetic and rehabilitative treatment within 
6 months from birth
Further clinical and blood examination with 
genetic investigation
TEOAE + AABR 
before discharge from hospital
PASS
S
T
O
P
PASS
REFER
PASS
REFER
REFER
Newborns without
risk factors
Cmv test on urine 
sample
Figure 1 Graphical algoritm of screening investigation in
neonates without audiological risk factors.
TEOAE + AABR 
(after 35 weeks of gestational age for preterm 
newborns)
Further audiological investigation
within 3 months of life
Prosthetic and rehabilitative treatment within 
6 months from birth
Further clinical and blood examination with 
genetic investigation
TEOAE + AABR are repeated
before discharge from hospital
PASS
S
T
O
P
PASS
REFER
PASS
REFER
REFER
Newborns with
risk factors
Cmv test on urine 
sample
Figure 2 Graphical algoritm of screening investigation in
neonates with audiological risk factors.
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such as furosemide, and hyperbilirubinemia that
requires exchange transfusion)
- family history of permanent childhood hearing loss
- family history of neurodegenerative disorders, such
as Hunter syndrome, or sensory motor neuropathies,
such as Friedreich ataxia and Charcot-Marie-Tooth
syndrome.
Neonates with auditory neuropathy risk factors
should undergo both automatic TEOAE and AABR
test before the discharge from the hospital (or within
30 days from birth if neonates are born in a level I
facility).
In premature neonates audiological screening should
be executed after 35 weeks of gestational age. If the test
p r o d u c e sap o s i t i v er e s u l ti ts h o u l db er e p e a t e db e f o r e
discharge or within two weeks. In all infants where
audiological tests produce a definitely positive result a
Cytomegalovirus (CMV) infection should be investigated
by detection of CMV DNA in urine. If the second test
still produces a positive result the infant should be sent
to level III ORL Department to perform further tests
within 3 months from birth.
B e f o r et h ei n f a n ti sd i s c h a r g e df r o mt h eh o s p i t a lt h e
person responsible for the screening should write the
screening results on the paediatric booklet (this booklet
will be given to the infant’sf a m i l yw h e nt h en e o n a t ei s
discharged from the hospital), on the screening’sr e s u l t s
register and on the online database. The person respon-
sible should specify which kind of test (TEOAE, AABR
or both) the neonate has undergone and what result
(positive or negative) the test has produced. The screen-
ing manager should also specify the timing for further
audiological investigation depending on neonate’sr i s k
factors. Parents should be given adequate information
on congenital hearing impairment if their neonate has
failed newborn hearing screening. Infants of a few
months of age re-admitted to hospital within because of
hyperbilirubinemia requiring exsanguino-transfusion or
for a sepsis diagnosed with positive culture should
repeat TEOAE and AABR test regardless to their neona-
tal screening result.
Infantile progressive deafness and late-onset hearing
impairment
Progressive and late-onset deafness account for about
20-30% of infantile hearing loss. These patients can
develop later hearing impairment even if the neonatal
audiological screening was successfully completed. The
o n l yw a yt oi d e n t i f yt h e mi st ok e e pm o n i t o r i n gi n f a n t s
with risk factors for progressive or late-onset hearing
impairment throughout their childhood regardless to
their neonatal audiological screening result. Patients
with the following risk factors should undergo at least
one audiological evaluation between 24 and 30 months
of age:
- neonatal intensive care of more than 5 days or any
of the following regardless of length of stay (ECMO,
assisted ventilation, exposure to ototoxic medications
such as gentamycin and tobramycin or loop diuretics
such as furosemide, and hyperbilirubinemia that
requires exchange transfusion),
- In-utero infections, such as herpes, rubella, syphilis,
and toxoplasmosis
- Craniofacial anomalies, including those that involve
the pinna, ear canal, ear tags, ear pits, and temporal
bone anomalies
- Physical findings, such as white forelock, that are
associated with a syndrome known to include a sen-
sorineural or permanent conductive hearing loss.
Boel test should be performed by the family paediatri-
cian as usual.
Patients with the risk factors listed below should
undergo audiological evaluation every 6-12 months till
3 years of age and then every 12 months till 6 years of
age.
- In-utero CMV infection
- family history of permanent childhood hearing loss
- Syndromes associated with hearing loss or pro-
gressive or late-onset hearing loss, such as neurofi-
bromatosis, osteopetrosis, and Usher syndrome;
other frequently identified syndromes include
Waardenburg, Alport, Pendred, and Jervell and
Lange-Nielson.
- Neurodegenerative disorders, such as Hunter syn-
drome, or sensory motor neuropathies, such as Frie-
dreich ataxia and Charcot-Marie-Tooth syndrome
- Culture-positive postnatal infections associated
with sensorineural hearing loss, including confirmed
bacterial and viral (especially herpes viruses and
varicella) meningitis
- Head trauma, especially basal skull/temporal bone
fracture that requires hospitalization
- Chemotherapy or ototoxic drugs
- Caregivers concern regarding hearing, speech, lan-
guage, or developmental delay
Boel test should be performed by the family paediatri-
cian as usual.
Family paediatricians should be part of his screening
program by investigating auditory function in infants
and children with and without risk factors during rou-
tine health checks at 3,6,8,12,18 months and at 3 and
6 years.
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Patients and methods
From 1993 to the 20th of november 2005 neonates with
audiological risk factors have been evaluated with clini-
cal ABR.
From the 20th of November 2005 all neonates born in
the University hospital of Pisa (which represents the
reference facility of the North-West Tuscany Area)
undergo newborn hearing screening. They execute the
test (TEOAE or AABR depending on the presence or
absence of auditory risk factors) before the discharge
from hospital or within 2 weeks from birth. This test,
and further investigations in newborns presenting posi-
tive test outcome (refer) can be performed thanks to the
collaboration between the U.O. Neonatologia, AOUP
and the Otology and Cochlear Implant Centre of the
University hospital of Pisa. TEOAE and AABR tests are
executed with the device Accuscreen Pro-GN Otometrics-
by an audiometrist with the collaboration of dedicated
medical personnel. Tests are performed following the
guidelines described above. TEOAE are executed on all
newborns. The test is repeated before discharge when
the first examination produces a positive result. If the
second test still produces a positive (refer)r e s u l tn e o -
nates undergo AABR test.
AABR are immediately executed in neonates with
audiological risk factors (risk factors are based on those
reported on the JCIH Position Statement 2000 and
2007). When AABR produces a positive result further
audiological tests are executed. Hearing impairment
severity degree is classified according to the BIAP
(Bureau International d’AudioPhonologie) criteria (mild
between 21 and 40 dB of hearing loss; medium between
41 and 70 dB; severe between 71 and 90 dB and pro-
found over 91 dB of hearing loss). If hearing loss (HL) is
confirmed further biochemical and instrumental tests
are carried out. When the cause of HL can’t be detected,
DNA is extracted from the Guthrie card which had been
stored in the first days from birth to search for CMV
genome. DNA is extracted with DNA blood minikit
(final eluition 50 uL) and visualized on agarosio gel.
Results
From the 20th of November 2005 to the 30th of April
2009 8113 neonates born in the Neonatal Unit of Santa
Chiara Hospital (Pisa) have undergone newborn hearing
screening (Table 1).
7621 neonates (93.9%) without risk factors executed
only the TEOAE test (they executed AABR only if the
first test was refer). 492 (6.1%) of them had audiological
risk factors and thus underwent TEOAE + AABR test.
84 patients (1,04%), among which 39 with risk factors
and 45 without risk factors failed both first (TEOAE)
and second level (AABR) tests. These 84 infants under-
went audiological evaluation at Otology and Cochlear
Implant Centre of the University hospital of Pisa. Only 6
of them (0.07% of the 8.113 neonates) (two with risk
factors and four without) didn’t execute further exami-
nations because parents didn’t agree to further tests
(2 cases); because the hospital was unable to get in
touch with the parents (2 cases); because of life-threa-
tening conditions (1 case); or because they died (1 case).
78 infants underwent clinical ABR and further tests. 24
resulted pass a tt h ef i r s tt e s t .1 5f a i l e dt h ef i r s tt e s tb u t
resulted pass at the second ABR test. In other 5 patients
the third examination with AABR gave a pass result.
Finally 44 patients resulted false-positives (the 0,54% of
the screened newborns).
34 neonates (4,2‰) had a final diagnosis of hearing
impairment. 8 patients (0.99‰) (only one had risk fac-
tors) had unilateral hearing loss (6 mild, 1 medium and
1 severe). 26 patients (3,2‰) had a final diagnosis of
bilateral hearing impairment : 5 mild (0,6‰), 11 med-
ium (1,4‰)a n d1 0( 1 , 2 ‰) severe/profound HL. 21 of
them (80,77%) had risk factors (9 neonates with severe
hearing impairment had risk factors: 7 had suffered
from neonatal respiratory distress, 1 had a family history
of deafness, 1 had craniofacial anomalies and had suf-
fered from neonatal respiratory distress). In one patient
auditory neuropathy was diagnosed.
Among the 26 bilaterally hearing impaired patients: 12
cases were prematurely born or had suffered from
respiratory problems (neonatal asphyxia or respiratory
distress); in 2 patients connexine 26 gene mutations
were found (heterozygous mutation V37I plus heterozy-
gous mutation V95M on GJB2 gene; heterozygous muta-
tion G59A on gene GJB2); 1 patient had family history
of infantile deafness; 4 patients had syndromes related
to hearing impairment (1 case of Charge syndrome with
the sporadic mutation c.5300+1G®Ti nt h eCHD7
gene; 1 case of Diamond Blackfan Anemia; 1 case of
5q11.2-q13 duplication; 1 case of malformative syn-
drome in a female with q11 deletion plus partial trisomy
of chromosome 6); 3 patients had congenital CMV
infections (one of them was positive for CMV and het-
erozygous mutation R127H on GJB2 gene).
In four neonates hearing loss was classified as idio-
pathic. DNA was extracted from the Guthrie card of
these 4 patients to search for CMV genome but the
result was negative.
Discussion and Conclusions
Universal newborn hearing screening represents the only
way to early identify neonates with hearing impairment.
If HL is treated precociously with a prosthetic/rehabili-
tative treatment within few months from birth, the
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have on the language development and on the future
communication capabilities of the baby can be mini-
mized or prevented [40-45].
TEOAE is the most adequate test because it is accu-
rate, economic and of simple and rapid execution
[22,41,46]. Following the guidelines of JCIH an addi-
tional test (AABR) has been introduced for neonates
with audiological risk factors [7,22]. AABR is necessary
to identify patients with auditory neuropathy but it is
also important to test neonates whose TEOAE test was
refer in order to reduce the number of falsepositives and
avoid further examinations.
The 20-30% of infant hearing impairment is repre-
sented by progressive or late-onset hearing loss. New-
born screening is not sufficient to identify this kind of
hearing impairment [39]. That’s the reason why it’s
necessary to establish an audiological follow-up pro-
gram, especially in infants at risk.
Our group has formulated, according to the work of
the 2007 JCIH Position Statement and other interna-
tional statements, the guidelines for the execution of the
audiological screening in Tuscany. The following are the
main peculiar contents of our guidelines for newborn
hearing screening.
￿ The risk factors for auditory neuropathy are investi-
gated with special attention
￿ A screening manager is nominated in each facility
￿ Tests are executed mainly by audiometrists with the
collaboration of dedicated and trained medical personnel
￿ Even when the screening is refer in only one side,
neonates undergo further audiological tests
￿ All hearing impaired newborns are early tested for
congenital exposure to CMV infection in order to dis-
tinguish it from CMV infections caught later
￿ An audiological follow-up program is advised in
patients with risk factors for progressive or late-onset
hearing loss.
In our screening program the percentage of false-
positive cases was quite low when compared to litera-
ture reports (0.54%). The 34.1% of false positive cases
are patients with risk factors.
We also underscore the importance of a follow-up in
newborn who have failed the newborn hearing screen-
ing. In some cases (24 were pass at the first ABR, 15 at
the 2nd, 5 at the 3rd) the hearing threshold of ABR
improved after the repetition of the test, probably in
relation to a maturation of the auditory system. Some
patients with hearing threshold lower than 40 dB at the
first ABR test gained a normal hearing threshold over a
follow-up of six months. Physiological immaturity of
central auditory nervous system and physiological nar-
rowness of auditory canal can thus explain most of false
positive results if audiological tests are performed in the
first few days after birth.
So before giving a final diagnosis we repeat the ABR
test 3 times at least in the first six months of age. The
incidence of bilateral hearing impairment in our experi-
ence (3.2‰) is a little higher than that found in interna-
tional and national literature.
Perhaps this difference is due to the fact that our data
have been collected in a level III facility with a neonatal
i n t e n s i v ec a r eu n i ts om a n yn e o n a t e sw h i c hh a v eb e e n
tested have undergone neonatal intensive care for more
than 5 days, they have required assisted ventilation, they
have been exposed to ototoxic medications or they have
gained high levels of hyperbilirubinemia (80.77% of neo-
nates with bilateral HL had audiological risk factors).
It’s important to identify the etiology of HL so that
the treatment can be more individualized. In our study
Table 1 Results of Pisa’s experience from the 20th of November 2005 to the 30th of April 2009
Total
number
Neonates with audiological risk factors Neonates without audiological risk factors
Screened neonates 8.113 492 (6.06%) 7621(93.9%)
Positive screening result at level II test 84 (1.04%) 39 (46.42%) 45 (53.57%)
False-positive results 44 (0.54%) 15 (34.09%) 29 (65.9%)
at first ABR 24 (54.5%) 9 15
at second ABR 15 (34.09%) 4 11
at third ABR 5 (11.36%) 2 3
No-show patients 6 2 4
Hearing impaired patients 34 (4.2‰)2 2 1 2
Unilaterally hearing impaired patients 8 (0.99‰)1 7
Bilaterally hearing impaired patients 26 (3.2 ‰) 21 (80.77%) 5 (19.23%)
mild HL 5 (0.6 ‰)
Medium HL 11 (1.4 ‰)
severe/profound HL 10 (1.2 ‰)
Ghirri et al. Italian Journal of Pediatrics 2011, 37:16
http://www.ijponline.net/content/37/1/16
Page 6 of 8we could not identify the causes of HL in only 4
patients. In 12 neonates (46.15% of bilaterally hearing
impaired patients) the main cause is premature birth or
neonatal respiratory distress.
The implementation of this screening program has
required a considerable organizational effort and the
employment of dedicated personnel which has absorbed
resources otherwise available to other audiological activ-
ities. Four patients referred to the screening program
did not turn up for the tests despite repeated invitations
from the hospital. This situation occurred in 4.76% of
the referred neonates - 0.05% of all the screened
patients. It’s also essential, in our opinion, family pedia-
tricians to be involved in a follow-up program in order
to detect children with progressive or lateonset HL.
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